KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Neogenomics (NEO) Leases (2016 - 2026)

Neogenomics filings provide 16 years of Leases readings, the most recent being $76.7 million for Q1 2026.

  • On a quarterly basis, Leases fell 1.41% to $76.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $76.7 million, a 1.41% decrease, with the full-year FY2025 number at $78.4 million, down 1.43% from a year prior.
  • Leases hit $76.7 million in Q1 2026 for Neogenomics, down from $78.4 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $102.0 million in Q1 2022 to a low of $76.7 million in Q1 2026.
  • Median Leases over the past 5 years was $86.6 million (2024), compared with a mean of $87.5 million.
  • Biggest five-year swings in Leases: soared 100.29% in 2022 and later decreased 13.28% in 2024.
  • Neogenomics' Leases stood at $96.1 million in 2022, then dropped by 4.52% to $91.8 million in 2023, then decreased by 13.28% to $79.6 million in 2024, then fell by 1.43% to $78.4 million in 2025, then dropped by 2.22% to $76.7 million in 2026.
  • The last three reported values for Leases were $76.7 million (Q1 2026), $78.4 million (Q4 2025), and $80.1 million (Q3 2025) per Business Quant data.